1. Home
  2. CHRS vs MRDN Comparison

CHRS vs MRDN Comparison

Compare CHRS & MRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$0.99

Market Cap

159.1M

Sector

Health Care

ML Signal

HOLD

Logo Meridian Holdings Inc. Common Stock

MRDN

Meridian Holdings Inc. Common Stock

SELL

Current Price

$11.09

Market Cap

155.1M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
CHRS
MRDN
Founded
2010
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
159.1M
155.1M
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
CHRS
MRDN
Price
$0.99
$11.09
Analyst Decision
Buy
Buy
Analyst Count
6
2
Target Price
$7.75
★ $19.73
AVG Volume (30 Days)
★ 1.7M
40.5K
Earning Date
11-05-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 472.00
N/A
EPS
N/A
★ 0.35
Revenue
N/A
★ $182,863,373.00
Revenue This Year
$44.19
$12.08
Revenue Next Year
$65.06
$10.93
P/E Ratio
★ N/A
$32.46
Revenue Growth
N/A
★ 21.01
52 Week Low
$0.97
$6.01
52 Week High
$2.62
$16.09

Technical Indicators

Market Signals
Indicator
CHRS
MRDN
Relative Strength Index (RSI) 36.72 35.44
Support Level $0.97 $10.68
Resistance Level $1.53 $14.76
Average True Range (ATR) 0.07 0.57
MACD -0.00 -0.03
Stochastic Oscillator 16.02 16.47

Price Performance

Historical Comparison
CHRS
MRDN

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

About MRDN Meridian Holdings Inc. Common Stock

Meridian Holdings Inc is engaged in the online gaming and betting business, providing sports betting, online casino, and gaming operations across multiple jurisdictions in Europe, Africa, and Central and South America. The company has three reportable segments: MeridianBet Group, GMAG, and RKings & CFAC. The MeridianBet Group segment includes retail and online sports betting, casinos, and related gaming operations. The GMAG segment focuses on the resale of third-party gaming content, mainly serving customers in the Asia-Pacific region. The RKings & CFAC segment is involved in pay-to-enter prize competitions and trade promotions conducted in the United Kingdom and Australia. It generates the majority of its revenue from the MeridianBet Group segment.

Share on Social Networks: